JP4728226B2 - Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法 - Google Patents
Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法 Download PDFInfo
- Publication number
- JP4728226B2 JP4728226B2 JP2006510307A JP2006510307A JP4728226B2 JP 4728226 B2 JP4728226 B2 JP 4728226B2 JP 2006510307 A JP2006510307 A JP 2006510307A JP 2006510307 A JP2006510307 A JP 2006510307A JP 4728226 B2 JP4728226 B2 JP 4728226B2
- Authority
- JP
- Japan
- Prior art keywords
- cdc42
- protein
- nuclear translocation
- inhibitor
- screening method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
ロバスタチン(化学名:(+)−(1S,3R,7S,8S,8aR)−1,2,3,7,8,8a−ヘキサヒドロ−3,7−ジメチル−8−[2−[(2R,4R)−テトラヒドロ−4−ヒドロキシ−6−オキソ−2H−ピラン−2−イル]エチル]−1−ナフチル (S)−2−メチルブチレート(米国特許第4,231,938号参照));
シンバスタチン(化学名:(+)−(1S,3R,7S,8S,8aR)−1,2,3,7,8,8a−ヘキサヒドロ−3,7−ジメチル−8−[2−[(2R,4R)−テトラヒドロ−4−ヒドロキシ−6−オキソ−2H−ピラン−2−イル]エチル]−1−ナフチル 2,2−ジメチルブタノエート(米国特許第4,444,784号参照));
プラバスタチン(化学名:(+)−(3R,5R)−3,5−ジヒドロキシ−7−[(1S,2S,6S,8S,8aR)−6−ヒドロキシ−2−メチル−8−[(S)−2−メチルブチリルオキシ]−1,2,6,7,8,8a−ヘキサヒドロ−1−ナフチル]ヘプタン酸(米国特許第4,346,227号参照));
フルバスタチン(化学名:(3RS,5SR,6E)−7−[3−(4−フルオロフェニル)−1−(1−メチルエチル)−1H−インドール−2−イル]−3,5−ジヒドロキシ−6−ヘプテン酸(米国特許第5,354,772号参照));
アトルバスタチン(化学名:(3R,5R)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−フェニルカルバモイル−1H−ピロル−1−イル]−3,5−ジヒドロキシヘプタン酸(米国特許第5,273,995号参照));
セリバスタチン(化学名:(3R,5S)−エリスロ−(E)−7−[4−(4−フルオロフェニル)−2,6−ジイソプロピル−5−メトキシメチル−ピリジン−3−イル]−3,5−ジヒドロキシ−6−ヘプテン酸(米国特許第5,177,080号参照));
メバスタチン(化学名:(+)−(1S,3R,7S,8S,8aR)−1,2,3,7,8,8a−ヘキサヒドロ−7−メチル−8−[2−[(2R,4R)−テトラヒドロ−4−ヒドロキシ−6−オキソ−2H−ピラン−2−イル]エチル]−1−ナフチル (S)−2−メチルブチレート(米国特許第3,983,140号参照));
ロスバスタチン(化学名:7−[4−(4−フルオロフェニル)−6−イソプロピル−2−(N−メチル−N−メタンスルホニルアミノピリミジン)−5−イル]−(3R,5S)−ジヒドロキシ−(E)−6−ヘプテン酸(米国特許第5,260,440号、日本国特許第2,648,897号参照));
ピタバスタチン((3R,5S,6E)−7−[2−シクロプロピル−4−(4−フルオロフェニル)−3−キノリル]−3,5−ジヒドロキシ−6−ヘプテン酸(米国特許第5,856,336号、日本国特許第2,569,746号参照))
これらは、製剤学的に必要であれば塩や溶媒和物として使用することもできる。特に好ましい阻害剤はピタバスタチンである。
以下、実施例により本発明を具体的に説明するが、本発明はこの実施例により何ら限定されるものではない。
1×10 個のHUVECを6ウエルのプレートに播種した後、1夜EGM−2培地で培養した。この細胞に、フゲネ6(Fugene6)を用いて、前記で調製したプラスミド構築物DNAを1ウエル当たり0.8μg添加した。さらに21時間EGM−2培地で培養した後、GFPによる蛍光を蛍光顕微鏡で観察した結果を図1に示す。
一方、プラスミド構築物DNAを添加したHUVECの培養を開始してから6時間後に、ピタバスタチンを最終濃度が1μMとなるように添加し、さらに静置して15時間培養した細胞をプレパラート上に固定し、蛍光顕微鏡で観察した結果を図2に示す。さらに、この細胞を核染色色素ヘキストで染色した結果を図3に示す。
また、本発明は、Cdc42タンパク質の核内への移行を測定することを特徴とする血管治療剤のスクリーニング方法を提供するものであり、血管病の新たな治療薬や予防薬を開発するための手法として産業上有用である。
Claims (3)
- 標識したCdc42タンパク質を発現しているHUVECに被検物質を添加し、標識したCdc42タンパク質の核内への移行を測定することからなる、Cdc42タンパク質の作用に起因する血管壁の障害を改善する物質のスクリーニング方法。
- 標識したCdc42タンパク質が蛍光蛋白質との融合タンパク質の形態であり、核内への移行の測定が蛍光として観察される、請求項1に記載のスクリーニング方法。
- 被検物質を添加した場合の核内で観察される標識量を、被検物質未添加の場合の標識量と比較する工程を含む、請求項1または2に記載のスクリーニング方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54707504P | 2004-02-25 | 2004-02-25 | |
US60/547,075 | 2004-02-25 | ||
PCT/JP2005/003008 WO2005079847A1 (ja) | 2004-02-25 | 2005-02-24 | Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005079847A1 JPWO2005079847A1 (ja) | 2007-10-25 |
JP4728226B2 true JP4728226B2 (ja) | 2011-07-20 |
Family
ID=34886288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006510307A Expired - Fee Related JP4728226B2 (ja) | 2004-02-25 | 2005-02-24 | Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8252524B2 (ja) |
EP (1) | EP1719525B1 (ja) |
JP (1) | JP4728226B2 (ja) |
WO (1) | WO2005079847A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309574B2 (en) * | 2004-02-25 | 2012-11-13 | Kowa Company, Ltd. | Nuclear transfer promoter for Rac protein and method of screening the same |
WO2005079847A1 (ja) | 2004-02-25 | 2005-09-01 | Kowa Company, Ltd. | Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法 |
CA2879103A1 (en) * | 2012-07-13 | 2014-01-16 | Jordan L. Holtzman | Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease |
WO2020000470A1 (zh) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | 促进cdc42蛋白过表达的重组载体及其构建方法 |
WO2023195509A1 (ja) * | 2022-04-08 | 2023-10-12 | 国立大学法人京都大学 | 血管内皮バリア破綻の阻害剤及びその使用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (ja) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5854259A (en) * | 1987-08-20 | 1998-12-29 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones |
US5185328A (en) * | 1987-08-20 | 1993-02-09 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis |
CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
KR0129653Y1 (ko) | 1993-09-17 | 1999-10-01 | 김광호 | 청소기의 흡입구체 |
PT814782E (pt) | 1995-12-22 | 2003-04-30 | Nissan Chemical Ind Ltd | Composicao farmaceutica estabilizada com um agente basico |
WO2005079847A1 (ja) | 2004-02-25 | 2005-09-01 | Kowa Company, Ltd. | Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法 |
US20070293535A1 (en) * | 2005-02-24 | 2007-12-20 | Kowa Company, Ltd. | Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame |
-
2005
- 2005-02-24 WO PCT/JP2005/003008 patent/WO2005079847A1/ja active Application Filing
- 2005-02-24 JP JP2006510307A patent/JP4728226B2/ja not_active Expired - Fee Related
- 2005-02-24 EP EP05719458.1A patent/EP1719525B1/en not_active Not-in-force
-
2009
- 2009-08-26 US US12/548,239 patent/US8252524B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8252524B2 (en) | 2012-08-28 |
EP1719525B1 (en) | 2014-12-10 |
JPWO2005079847A1 (ja) | 2007-10-25 |
WO2005079847A1 (ja) | 2005-09-01 |
US20100221766A1 (en) | 2010-09-02 |
EP1719525A1 (en) | 2006-11-08 |
EP1719525A4 (en) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100815042B1 (ko) | 이형접합성 가족성 고콜레스테롤혈증 치료에 있어서로수바스타틴(zd-4522)의 용도 | |
Frick et al. | Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells | |
Vlahopoulos et al. | New use for old drugs? Prospective targets of chloroquines in cancer therapy | |
Rawlings et al. | Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event | |
JP4728226B2 (ja) | Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法 | |
US20090062369A1 (en) | Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels | |
AU2012275190B2 (en) | Compositions, methods and kits for treating leukemia | |
US20080161348A1 (en) | Ptx3-gene expression inhibitor | |
JP4892477B2 (ja) | 新規なトリグリセリド低下剤 | |
JP4711952B2 (ja) | Racタンパク質の核内移行促進剤及びそのスクリーニング方法 | |
US20100093010A1 (en) | Inhibitor for the Formation of Gamma-Secretase Complex | |
US20070293535A1 (en) | Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame | |
US20040087597A1 (en) | Preventives and remedies for complications of diabetes | |
US20080275081A1 (en) | Novel thrombomodulin expression promoters | |
JP4719572B2 (ja) | Lklf/klf2遺伝子発現促進剤 | |
JPWO2005063294A1 (ja) | γ−セクレターゼ複合体形成阻害剤 | |
Dent et al. | Kinase inhibitors: look beyond the label on the bottle | |
Ferrara et al. | Diverse effects of statins on endothelial cells? | |
JPWO2019177159A1 (ja) | 癌免疫療法併用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071217 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101102 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101227 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101228 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110405 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110414 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140422 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |